MannKind Co. (NASDAQ:MNKD) Shares Sold by Tudor Investment Corp ET AL

Tudor Investment Corp ET AL lowered its holdings in shares of MannKind Co. (NASDAQ:MNKD) by 45.0% in the fourth quarter, HoldingsChannel.com reports. The fund owned 78,382 shares of the biopharmaceutical company’s stock after selling 64,087 shares during the quarter. Tudor Investment Corp ET AL’s holdings in MannKind were worth $504,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Vanguard Group Inc. increased its stake in shares of MannKind by 2.7% during the 4th quarter. Vanguard Group Inc. now owns 16,058,557 shares of the biopharmaceutical company’s stock worth $103,257,000 after purchasing an additional 420,334 shares in the last quarter. Geode Capital Management LLC grew its holdings in MannKind by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 6,374,274 shares of the biopharmaceutical company’s stock valued at $40,996,000 after buying an additional 35,346 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its holdings in shares of MannKind by 275.9% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 4,887,609 shares of the biopharmaceutical company’s stock worth $31,427,000 after acquiring an additional 3,587,484 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of MannKind by 40.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,958,219 shares of the biopharmaceutical company’s stock valued at $19,022,000 after acquiring an additional 855,261 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of MannKind by 2.0% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,270,106 shares of the biopharmaceutical company’s stock valued at $14,597,000 after acquiring an additional 45,277 shares during the last quarter. Hedge funds and other institutional investors own 49.55% of the company’s stock.

MannKind Trading Down 4.4 %

MNKD stock opened at $4.64 on Friday. The company has a market cap of $1.41 billion, a PE ratio of 66.21 and a beta of 1.14. The stock has a 50-day moving average price of $4.90 and a two-hundred day moving average price of $5.84. MannKind Co. has a 12-month low of $4.17 and a 12-month high of $7.63.

MannKind (NASDAQ:MNKD) last issued its earnings results on Thursday, May 8th. The biopharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.03 by $0.01. The business had revenue of $78.35 million during the quarter, compared to analysts’ expectations of $75.86 million. MannKind had a negative return on equity of 17.74% and a net margin of 8.07%. The company’s revenue for the quarter was up 18.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.05 EPS. Equities analysts forecast that MannKind Co. will post 0.1 EPS for the current fiscal year.

Analysts Set New Price Targets

MNKD has been the subject of a number of recent research reports. StockNews.com upgraded shares of MannKind from a “hold” rating to a “buy” rating in a report on Wednesday, March 19th. Wedbush reiterated an “outperform” rating and issued a $11.00 price target on shares of MannKind in a report on Thursday, February 27th. Finally, Mizuho assumed coverage on MannKind in a report on Thursday, April 10th. They set an “outperform” rating and a $12.00 price objective on the stock. Eight equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $9.56.

About MannKind

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.